Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
An announcement from Tryptamine Therapeutics ( (AU:TYP) ) is now available.
Tryptamine Therapeutics Limited has announced a change in the indirect interests of its director, Mark Davies, effective January 16, 2025. The update reveals that 2,000,000 director options with a vesting condition could not be met by December 31, 2024, resulting in their lapse. This change in director’s interest does not involve any trade during a closed period, indicating compliance with ASX regulations.
More about Tryptamine Therapeutics
YTD Price Performance: -7.50%
Average Trading Volume: 4,025,654
Technical Sentiment Consensus Rating: Hold
Current Market Cap: A$47.23M
For a thorough assessment of TYP stock, go to TipRanks’ Stock Analysis page.
